E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Investigative Techniques [E05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048925 |
E.1.2 | Term | Acoustic schwannoma |
E.1.2 | System Organ Class | 100000014065 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objektive of this study is to test whether the new radio tracer 68Ga-NODAGA-E[c(RGDyK)]2 for PET imaging of angiogenises. The tracer combined with PET-MR has the potential to provide a novel non-invasive prognostic method for the growth rate of vestibularis schwannomas, as the growth rate of vestibularis schwannomas has been correlated with pro-angiogenetic markers. This is a phase II trial in patients with a benign intracranial tumor. Uptake of the tracer will be correlated to the growth rate by PET-MR and MR scans. |
|
E.2.2 | Secondary objectives of the trial |
Tumor uptake of 68Ga-NODAGA-E[c(RGDyK)]2 will be compared to the expression of pro-angiogenetic marker using RNA sequencing in tumor tissue obtained from operative removal of the tumor. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients who are either newly diagnosed with a MR-confirmed vestibularis schwannoma or patients who have been in the wactfull waiting regime for under 12 month and have only received 1 controlscan. The patients must be capable of understanding and giving informed written consent. |
|
E.4 | Principal exclusion criteria |
• Pregnancy • Non-MR compatible implants • Lactation • claustrofobi • Hormone treatment incl. birthcontrol pills • Steroid treatment • Obesity (> 140 kg) • Known allergy to the PET-tracer 68Ga-NODAGA-E[c(RGDyK)]2
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The correlation between the quantative tumor uptake of the PET-tracer 68Ga-NODAGA-E[c(RGDyK)]2 and the tumors growth rate decided by an additional MR-scan minimum 2 month later. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The patients will undergo a PET/MR-scan and an additional MR-scan minimum 2 month after the PET/MR-scan. These timepoints will be used to determine the tumoruptake as well as the growth rate. |
|
E.5.2 | Secondary end point(s) |
The correlation between the quantative tumor uptake of the PET-tracer 68Ga-NODAGA-E[c(RGDyK)]2 and the expression of pro-angiogenetic markers via RNA sequencing. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The correlation between the tumoruptake and the expression of the pro-angiogenetic markers. The time points is the PET/MR-scan as well as the RNA sequencing of the tumortissue obtained from surgery. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |